Shares of Solid Biosciences (NASDAQ:SLDB) jumped ~88% in the premarket on Tuesday after the gene therapy developer reported ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data.

Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Solid Biosciences has reported promising initial findings from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a gene therapy aimed at treating Duchenne muscular dystrophy. Data from the first ...

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...

Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% ...

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular ...